What is the efficacy of Trametinib combined with dabrafenib?

Trametinib and dabrafenib are a combination of drugs used together to treat malignant melanoma, a type of skin cancer. These two drugs are targeted therapies that prevent tumor growth and spread by inhibiting cell signaling pathways.

According to the results of multiple clinical trials, trametinib combined with dabrafenib has shown good efficacy in the treatment of malignant melanoma. Patients taking this drug combination showed higher survival rates and longer progression-free survival than those taking trametinib or dabrafenib alone. In addition, the drug combination significantly reduces the risk of malignant melanoma recurrence or metastasis. Each patient's situation is different, and results may vary from person to person. The best treatment method should be determined by the doctor based on the patient's specific situation and disease stage.

The original drug of trametinib has been launched in China and has entered the scope of Class B medical insurance, but it may only be purchased by patients who meet the indications of trametinib, such as BRAF V600 mutation-positive unresectable or metastatic melanoma. Its price is around 10,000 to 20,000 yuan. The reimbursement ratio is different in different regions, and the price is also different, making it expensive. The price of the Turkish version of the original drug Trametinib listed overseas is around RMB 7,900 (the price may fluctuate due to the exchange rate). Generic trametinib is also produced in other countries. The price of the Lao pharmaceutical factory is around RMB 2,950 (the price may fluctuate due to the exchange rate). The ingredients and efficacy of foreign generic drugs are basically the same as those of domestic and foreign original drugs.